Patents by Inventor Ruth Greferath
Ruth Greferath has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230248780Abstract: The present invention relates, in part, to cell-based gene therapies, including those targeting, by way of non-limiting example, TDP43 and A? aggregates, for the use in neurodegenerative disorders, including without limitation Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease, respectively.Type: ApplicationFiled: October 14, 2022Publication date: August 10, 2023Inventors: Claude NICOLAU, Claudine KIEDA, Reynald THINARD, Ruth GREFERATH, Melanie CHEVALIER
-
Publication number: 20220000935Abstract: The present invention relates, in part, to cell-based gene therapies, including those targeting, by way of non-limiting example, TDP43 and A? aggregates, for the use in neurodegenerative disorders, including without limitation Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease, respectively.Type: ApplicationFiled: November 6, 2019Publication date: January 6, 2022Inventors: Claude NICOLAU, Claudine KIEDA, Reynald THINARD, Ruth GREFERATH, Melanie CHEVALIER
-
Patent number: 9975946Abstract: The present invention comprises novel compositions and methods for eliciting high immune responses, of great specificity yielding conformationally sensitive antibodies. These antibodies recognize specific epitopes on a wide variety of antigens including but not limited to, amyloid protein, prion protein, P170 glycoprotein. The novel compositions of the invention comprise supramolecular antigenic constructs generally comprising a peptide sequence, covalently attached to pegylated lysine resulting in modified and enhanced peptide presentation. The unique modification methodology of the present invention is applicable to a variety of peptides and can ultimately be employed in therapeutic formulations and vaccines for diseases and disorders such as Alzheimer's disease.Type: GrantFiled: November 26, 2014Date of Patent: May 22, 2018Assignee: AC Immune SAInventors: Yves Claude Nicolau, Ruth Greferath, David Hickman
-
Publication number: 20160067267Abstract: The present invention provides for novel treatments of obesity and overweight and related disorders. The invention provides, in part, method of treatment comprising, or uses of inositol-tripyrophosphate (ITPP) in these disease states.Type: ApplicationFiled: March 14, 2014Publication date: March 10, 2016Applicant: NormOxys, Inc.Inventors: Ruth Greferath, Jean-Marie Lehn, Yves Claude Nicolau
-
Patent number: 9078908Abstract: The present invention comprises compounds, compositions thereof, and methods capable of delivering modified inositol hexaphospahte (IHP) comprising an internal pyrophosphate ring to the cytoplasm of mammalian cells. In certain embodiments, the present invention relates to compounds, compositions thereof, and methods that enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to the cytoplasm of the red blood cells.Type: GrantFiled: June 20, 2013Date of Patent: July 14, 2015Assignee: NormOxys, Inc.Inventors: Yves Claude Nicolau, Jean-Marie Lehn, Konstantina C. Fylaktakidou, Ruth Greferath
-
Publication number: 20150183857Abstract: The present invention comprises novel compositions and methods for eliciting high immune responses, of great specificity yielding conformationally sensitive antibodies. These antibodies recognize specific epitopes on a wide variety of antigens including but not limited to, amyloid protein, prion protein, P170 glycoprotein. The novel compositions of the invention comprise supramolecular antigenic constructs generally comprising a peptide sequence, covalently attached to pegylated lysine resulting in modified and enhanced peptide presentation. The unique modification methodology of the present invention is applicable to a variety of peptides and can ultimately be employed in therapeutic formulations and vaccines for diseases and disorders such as Alzheimer's disease.Type: ApplicationFiled: November 26, 2014Publication date: July 2, 2015Inventors: Yves Claude Nicolau, Ruth Greferath, David Hickman
-
Patent number: 8926983Abstract: The present invention comprises novel compositions and methods for eliciting high immune responses, of great specifity yielding conformationally sensitive antibodies. These antibodies recognize specific epitopes on a wide variety of antigens including but not limited to, amyloid protein, prion protein, P170 glycoprotein. The novel compositions of the invention comprise supramolecular antigenic constructs generally comprising a peptide sequence, covalently attached to pegylated lysine resulting in modified and enhanced peptide presentation. The unique modification methodology of the present invention is applicable to a variety of peptides and can ultimately be employed in therapeutic formulations and vaccines for diseases and disorders such as Alzheimer's disease.Type: GrantFiled: February 22, 2005Date of Patent: January 6, 2015Assignee: AC Immune SAInventors: Yves Claude Nicolau, Ruth Greferath, David Hickman
-
Publication number: 20140194391Abstract: The present invention relates to mixed calcium/sodium salt of inositol tripyrophosphate, methods of preparing and methods of use. The mixed calcium/sodium salt may be a monocalcium tetrasodium salt of inositol tripyrophosphate. Methods of use include administering the above salts in an effective amount to treat diseases caused by hypoxia or other conditions associated with inadequate function of the lungs or circulatory system, such as various types of cancer and Alzheimer's disease.Type: ApplicationFiled: November 8, 2013Publication date: July 10, 2014Applicants: Universite de Strasbourg, NormOxys, Inc.Inventors: Yves Claude Nicolau, Jean-Marie Lehn, Konstantina C. Fylaktakidou, Ruth Greferath
-
Publication number: 20140170127Abstract: The present invention comprises compounds, compositions thereof, and methods capable of delivering modified inositol hexaphospahte (IHP) comprising an internal pyrophosphate ring to the cytoplasm of mammalian cells. In certain embodiments, the present invention relates to compounds, compositions thereof, and methods that enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to the cytoplasm of the red blood cells.Type: ApplicationFiled: June 20, 2013Publication date: June 19, 2014Inventors: Yves Claude NICOLAU, Jean-Marie LEHN, Konstantina C. FYLAKTAKIDOU, Ruth GREFERATH
-
Patent number: 8663650Abstract: The present invention comprises novel compositions and methods for eliciting high immune responses, of great specifity yielding conformationally sensitive antibodies. These antibodies recognize specific epitopes on a wide variety of antigens including but not limited to, amyloid protein, prion protein, P170 glycoprotein. The novel compositions of the invention comprise supramolecular antigenic constructs generally comprising a peptide sequence, covalently attached to pegylated lysine resulting in modified and enhanced peptide presentation. The unique modification methodology of the present invention is applicable to a variety of peptides and can ultimately be employed in therapeutic formulations and vaccines for diseases and disorders such as Alzheimer's disease.Type: GrantFiled: October 4, 2004Date of Patent: March 4, 2014Assignee: AC Immune SAInventors: Yves Claude Nicolau, Ruth Greferath, David Hickman
-
Publication number: 20130059820Abstract: The present invention comprises compounds, compositions thereof, and methods capable of delivering modified inositol hexaphosphate (IHP) comprising an internal pyrophosphate ring to the cytoplasm of mammalian cells. In certain embodiments, the present invention relates to compounds, compositions thereof, and methods that enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to the cytoplasm of the red blood cells.Type: ApplicationFiled: March 21, 2012Publication date: March 7, 2013Applicant: NORMOXYS, INC.Inventors: Yves Claude NICOLAU, Jean-Marie LEHN, Konstantina FYLAKTAKIDOU, Ruth GREFERATH
-
Publication number: 20120288896Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).Type: ApplicationFiled: July 25, 2012Publication date: November 15, 2012Applicant: AC IMMUNE S.A.Inventors: Ruth Greferath, Andreas Muhs, Andrea Pfeifer, Claude Nicolau
-
Publication number: 20120244165Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).Type: ApplicationFiled: May 1, 2012Publication date: September 27, 2012Applicant: AC Immune S.A.Inventors: Ruth Greferath, Andreas Muhs, Andrea Pfeifer, Claude Nicolau
-
Patent number: 8178514Abstract: The present invention comprises compounds, compositions thereof, and methods capable of delivering modified inositol hexaphosphate (IHP) comprising an internal pyrophosphate ring to the cytoplasm of mammalian cells. In certain embodiments, the present invention relates to compounds, compositions thereof, and methods that enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to the cytoplasm of the red blood cells.Type: GrantFiled: February 10, 2011Date of Patent: May 15, 2012Assignee: Normoxys, Inc.Inventors: Yves Claude Nicolau, Jean-Marie Lehn, Konstantina C. Fylaktakidou, Ruth Greferath
-
Publication number: 20120045463Abstract: The present invention comprises novel compositions and methods for eliciting high immune responses, of great specifity yielding conformationally sensitive antibodies. These antibodies recognize specific epitopes on a wide variety of antigens including but not limited to, amyloid protein, prion protein, P170 glycoprotein. The novel compositions of the invention comprise supramolecular antigenic constructs generally comprising a peptide sequence, covalently attached to pegylated lysine resulting in modified and enhanced peptide presentation. The unique modification methodology of the present invention is applicable to a variety of peptides and can ultimately be employed in therapeutic formulations and vaccines for diseases and disorders such as Alzheimer's disease.Type: ApplicationFiled: October 4, 2004Publication date: February 23, 2012Inventors: Yves Nicolau, Ruth Greferath, David Hickman
-
Publication number: 20120035137Abstract: Inositol-tripyrophosphate is an allosteric effector of hemoglobin due to its ability to cross the plasma membrane of red blood cells and deliver oxygen to solid tumors, by lowering the oxygen affinity of the hemoglobin of red blood cells. The present invention is directed to the use of inositol-tripyrophosphate to reduce hemoglobin's affinity for oxygen in circulating red blood cells. The present invention is further directed to the use of inositol-tripyrophosphate to inhibit angiogenesis and enhance radiation sensitivity of hypoxic tumors. The present invention is further directed to the use of inositol-tripyrophosphate for the treatment of various types of cancers, Alzheimer's disease, stroke and osteoporosis.Type: ApplicationFiled: June 24, 2011Publication date: February 9, 2012Inventors: Konstantina C. Fylaktakidou, Jean-Marie Lehn, Claude Nicolau, Ruth Greferath
-
Publication number: 20120010174Abstract: The present invention relates to mixed calcium/sodium salt of inositol tripyrophosphate, methods of preparing and methods of use. The mixed calcium/sodium salt may be a monocalcium tetrasodium salt of inositol tripyrophosphate. Methods of use include administering the above salts in an effective amount to treat diseases caused by hypoxia or other conditions associated with inadequate function of the lungs or circulatory system, such as various types of cancer and Alzheimer's disease.Type: ApplicationFiled: July 5, 2011Publication date: January 12, 2012Applicant: Normoxys, Inc.Inventors: Yves Claude NICOLAU, Jean-Marie Lehn, Konstantina C. Flyaktakidou, Ruth Greferath
-
Publication number: 20120003161Abstract: Inositol-tripyrophosphate is an allosteric effector of hemoglobin due to its ability to cross the plasma membrane of red blood cells and deliver oxygen to solid tumors, by lowering the oxygen affinity of the hemoglobin of red blood cells. The present invention is directed to the use of inositol-tripyrophosphate to reduce hemoglobin's affinity for oxygen in circulating red blood cells. The present invention is further directed to the use of inositol-tripyrophosphate to inhibit angiogenesis and enhance radiation sensitivity of hypoxic tumors. The present invention is further directed to the use of inositol-tripyrophosphate to enhance PO2 in hypoxic tumors.Type: ApplicationFiled: August 18, 2011Publication date: January 5, 2012Applicant: NORMOXYS, INC.Inventors: Claude Nicolau, Ruth Greferath, Konstantina C. Fylaktakidou, Jean-Marie Lehn
-
Publication number: 20110294732Abstract: The present invention provides methods and compositions to replace up to 90% of erythropoietin use in the treatment of anemias and hypoxias. The method employs acid and salt forms of inositol-tripyrophosphate (ITPP) isomers to shift the P50 value of hemoglobin, thereby improving the rate and efficiency of oxygenation by blood even when red blood cell counts are low. Indications for the new method include anemias and hypoxia arising from infection, chemotherapy, premature birth, altitude change, compromised lung or heart function, aplastic anemia and anemia associated with a myelodysplastic syndrome, and other causes.Type: ApplicationFiled: July 5, 2011Publication date: December 1, 2011Applicants: Universite De Strasbourg, Normoxys, Inc.Inventors: Claude NICOLAU, Jean-Marie Lehn, Ruth Greferath
-
Publication number: 20110281825Abstract: The present invention comprises compounds, compositions thereof, and methods capable of delivering modified inositol hexaphosphate (IHP) comprising an internal pyrophosphate ring to the cytoplasm of mammalian cells. In certain embodiments, the present invention relates to compounds, compositions thereof, and methods that enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to the cytoplasm of the red blood cells.Type: ApplicationFiled: February 10, 2011Publication date: November 17, 2011Applicant: NormoxysInventors: Yves Claude NICOLAU, Jean-Marie LEHN, Konstantina FYLAKTAKIDOU, Ruth GREFERATH